Hepatitis B Newborn Screening and Immediate Birth-Dose Protocol
Hepatitis B newborn screening starts with maternal HBsAg testing during pregnancy to identify infants needing immediate intervention. The birth-dose hepatitis B vaccine is recommended within 12 to 24 hours of life for all neonates, especially those born to HBsAg-positive mothers, to reduce vertical transmission risk. The World Health Organization and CDC emphasize that timely birth-dose administration can lower mother-to-child transmission rates by over 90 percent when combined with hepatitis B immune globulin for high-risk infants. The CDC immunization schedule for hepatitis B newborn doses is available at CDC Child and Adolescent Immunization Schedules.
In the United States, universal hepatitis B newborn vaccination has been part of the recommended immunization schedule since 1991, leading to a significant decline in pediatric chronic infections. Hospitals are required to document the hepatitis B birth dose in the newborn's medical record and provide the mother with a vaccine information statement. The Advisory Committee on Immunization Practices updates its recommendations based on the latest safety and efficacy data, and its recent statements on birth-dose timing can be reviewed at ACIP Recommendations on the CDC website.
Treatment Options and Follow-Up Testing for Hepatitis B Newborns
Hepatitis B Immune Globulin and Antiviral Prophylaxis
For hepatitis B newborns born to HBsAg-positive or unknown-status mothers, hepatitis B immune globulin is administered within 12 hours alongside the first vaccine dose to provide passive antibody protection. In some high-viral-load cases, maternal antiviral therapy during pregnancy, such as tenofovir, is used to further reduce transmission risk, with postpartum infant follow-up guided by serologic testing. The FDA-approved hepatitis B vaccine formulations for neonates include Engerix-B and Recombivax HB, and product labeling is maintained by the manufacturers and accessible via FDA Vaccines, Blood, and Biologics.
Post-Vaccination Serologic Testing
Hepatitis B newborn follow-up includes anti-HBs and HBsAg testing at 9 to 12 months of age to confirm seroprotection and rule out infection. Infants who do not respond to the primary series may receive additional doses, and non-responders are evaluated for possible booster immunization or further testing. The WHO position paper on hepatitis B vaccines provides updated guidance on post-vaccination testing and is available at WHO Position Paper on Hepatitis B Vaccines.
Global Incidence, Prevention Rankings, and Industry Efforts
Global Burden and Prevention Rankings
Hepatitis B remains a leading cause of cirrhosis and liver cancer worldwide, with the highest chronic infection rates in the WHO Western Pacific and African regions. The global birth-dose coverage for hepatitis B newborn vaccination was approximately 45 percent in 2022, with countries like Taiwan and Thailand achieving over 90 percent coverage through universal infant programs. Gavi, the Vaccine Alliance, supports hepatitis B vaccine introduction in low-income countries, and its latest coverage data and country rankings can be found at Gavi, the Vaccine Alliance.
Pharmaceutical Companies and Vaccine Supply
Major manufacturers such as Merck, GlaxoSmithKline, and Sanofi produce hepatitis B vaccines used in newborn immunization programs, with